SPOTLIGHT: PerkinElmer paying $300M for ViaCell

PerkinElmer is buying ViaCell for $300 million, aiming to grow the latter's cord-blood banking business and spin off its drug-discovery unit, which is working on stem-cell-based remedies for cancer, heart disease, and diabetes. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.